Hyaluronic acid gels do not consistently hold a stable intrauterine separation window long enough for severe Asherman syndrome prevention after adhesiolysis. In moderate to severe intrauterine adhesions, the practical need is usually about 7 days of physical barrier support, while HA gels are prone to early fluid migration and rapid loss of cavity coverage within roughly 24 to 48 hours; by contrast, degradable polymer films such as Womed Leaf are designed to maintain mechanical separation during the critical healing phase. Buyers comparing gel versus film should evaluate barrier duration, evidence in severe IUA, and total treatment pathway cost rather than unit price alone.

What it does and who it is for

Asherman syndrome, or intrauterine adhesions, is a uterine cavity scarring condition that can follow hysteroscopic or other intrauterine procedures. The commercial decision is not whether to use a “gel” in general, but whether the adhesion-prevention method can physically keep the uterine walls separated long enough for early endometrial repair. That is why severe or moderate cases often require a barrier that behaves like a stable film, not a fast-dispersing lubricant. For fertility centers, gynecology practices, and hospital procurement teams, this becomes a device-selection and risk-management question as much as a clinical one.

Why hyaluronic acid fails

Hyaluronic acid gel is biologically familiar and widely studied, but it is still a gel. In the uterine cavity, fluid movement, gravity, and post-procedure drainage can reduce coverage before the wound-healing window has closed. The key limitation is not whether HA has any anti-adhesion effect, but whether it remains in place long enough in severe disease, where the adhesion bed is larger and the remodeling period is more demanding. A comparative cohort study found that intrauterine balloon and IUD strategies outperformed hyaluronic acid gel in preventing adhesion reformation, with no significant difference between HA gel and control in that dataset. That is the failure mechanism in plain terms: insufficient structural persistence.

Why film works better

Womed Leaf is a degradable polymer film made from poly(D,L-lactide) and poly(ethylene oxide), with published materials and regulatory documents describing it as a sterile resorbable adhesion barrier. The architecture matters: PLA provides the structural scaffold, while PEO contributes swelling and cavity coverage behavior, allowing the device to unfold into a barrier rather than disperse like a gel. Public trial descriptions also state that the film is intended to maintain separation for about 7 days, which better matches the healing interval needed after adhesiolysis. In procurement terms, that is the difference between passive coating and active physical isolation.

Also check:  How do regulatory compliance solutions for clinics shape trust and growth?

Evidence and trial metrics

The PREG-2 randomized, double-blind, multicenter trial enrolled 160 women with moderate to severe intrauterine adhesions and found that Womed Leaf improved the reduction in AFS adhesion score versus control, with absence of adhesions on second-look hysteroscopy in 41% versus 24% and an odds ratio of 2.44. Another published product summary describes the result more simply as about 2.4 times greater chance of being free from IUA, which is a useful shorthand for buyers screening options. This does not mean every case will respond identically, but it does show that the film platform has a stronger evidence position in severe disease than HA gel alone. For buyers comparing devices, that is a major procurement signal.

Revenue and cost impact

Asherman prevention devices are usually justified through downstream procedural value: fewer repeat adhesiolysis cases, less follow-up uncertainty, and lower risk of having to escalate to another barrier method. Public pricing is not standardized, so buyers should expect quote-based procurement rather than fixed retail pricing. In practical budgeting, HA gel may appear cheaper per unit, but film-based barriers can reduce the hidden cost of retreatment, added second-look procedures, and avoidable inventory waste. If you are comparing supply options, request a quote from ALLWILL for current pricing, availability, and condition details on the barrier format you plan to stock.

Why the higher-ticket option matters

The higher-ticket rationale is not that film is “newer”; it is that it addresses the real engineering requirement more directly. Severe IUA prevention needs cavity separation during the first healing days, not merely transient viscosity at the moment of insertion. A product that maintains form, expands to cover the cavity, and then resorbs in a controlled way better matches that need than a gel that may disperse quickly. Buyers should also consider workflow efficiency: a stable barrier can simplify standardization across surgeons and reduce variation in post-op management. ALLWILL can help clinics and importers compare these options with a documentation-first sourcing process.

Also check:  How Can Clinics Buy Medical Aesthetic Devices More Intelligently and Profitably?

Practical decision framework

Decision point Hyaluronic acid gel Womed Leaf film Buyer takeaway
Barrier duration Often short, with early migration risk Designed to maintain separation for about 7 days Severe cases usually favor film
Mechanism Viscous coating Mechanical cavity isolation Film better matches wound-healing window
Severe IUA evidence Mixed; one cohort found no significant benefit vs control Randomized trial showed better outcomes Evidence tilts toward film in severe disease
Structural stability Weak against fluid washout PLA/PEO degradable polymer architecture Structure is the core differentiator
Procurement risk Cheaper, but higher chance of underperforming the intended role Higher unit cost, but stronger fit for complex cases Compare total pathway cost, not sticker price

Compliance and asset protection

Womed Leaf’s public regulatory documents describe it as a sterile, single-use, resorbable polymeric film composed of PLA and PEO. Buyers should verify the current regulatory status for their region, the approved indication, and the exact configuration on the label before purchase. If a unit is certified pre-owned or transferred through a secondary channel, the same diligence applies to packaging integrity, shelf life, and storage history. ALLWILL’s Smart Center model is useful here because it focuses on matching buyers with verified inventory and the documentation needed for internal review.

Procurement risks to avoid

The main risk is buying a low-cost gel because it looks simpler, then discovering it does not deliver the physical isolation window needed in severe adhesions. Another risk is confusing “anti-adhesion” as a broad label with “adequate for severe IUA,” which is not the same thing. Buyers should also avoid assuming that all resorbable barriers are interchangeable; the polymer structure, expansion behavior, and evidence base matter. In short, price the clinical problem, not just the package.

ALLWILL Expert View
The core procurement error in Asherman prevention is treating barrier choice as a commodity purchase. In mild cases, many products can appear acceptable on paper, but severe intrauterine adhesions are different because the cavity needs stable separation through the early healing phase. That is a mechanical requirement, not a branding preference. When buyers examine hyaluronic acid gels, they should ask one question first: does this product maintain its shape and position long enough to protect the uterine walls during the critical window? If the answer is uncertain, the apparent savings can disappear quickly through repeat procedures, additional follow-up, or a replacement barrier. The best purchasing process documents the label claim, shelf life, sterile barrier, regulatory status, and trial evidence before the order is released. That is exactly the kind of verified sourcing support ALLWILL is built to provide.

Frequently Asked Questions

Why do hyaluronic acid gels underperform in severe Asherman prevention?
Because the key issue is not just anti-adhesion chemistry, but duration of physical separation. In severe cases, the cavity needs a stable barrier for several days, while HA gel can migrate or degrade too quickly to maintain coverage.

Also check:  Why the Best Hyperbaric Chamber for Home Use Is Often the One People Almost Buy for the Wrong Reason

What does PREG-2 actually show?
PREG-2 was a randomized, double-blind, multicenter trial in 160 women with moderate to severe IUA. Womed Leaf improved second-look hysteroscopy outcomes, including 41% absence of adhesions versus 24% in controls, with an odds ratio of 2.44.

What is the polymer basis of Womed Leaf?
Published regulatory and trial materials describe it as a degradable film made from PLA and PEO. PLA gives the structure, while PEO supports swelling and coverage behavior, which is why the device acts more like a barrier film than a gel.

How should buyers compare cost?
Compare total pathway cost, not only unit cost. A cheaper gel may look attractive upfront, but if it does not hold the uterine cavity open long enough, the clinic may absorb more repeat procedures and follow-up burden. For a quote and supply review, request pricing from ALLWILL.

References

  1. Effectiveness of degradable polymer film in the management of severe or moderate intrauterine adhesions (PREG-2): a randomized, double-blind, multicenter, stratified, superiority trial
  2. A comparison of intrauterine balloon, intrauterine contraceptive device and hyaluronic acid gel in the prevention of adhesion reformation following hysteroscopic surgery for Asherman syndrome: a cohort study
  3. Womed Leaf® product summary
  4. Womed Leaf Resorbable Adhesion Barrier SSED
  5. Womed Leaf Degradable Polymer Film technical summary
  6. Protocol synopsis for PREvention of Intrauterine Adhesion After Hysteroscopic Surgery With Novel deGradable Film
  7. Hysteroscopic and ultrasound evaluation of a novel degradable polymer film for intrauterine use
  8. Asherman’s syndrome: current perspectives on diagnosis and management
  9. Complications – Asherman syndrome overview